4.7 Article

Natalizumab Dosage Suspension: Are We Helping or Hurting?

Journal

ANNALS OF NEUROLOGY
Volume 68, Issue 3, Pages 395-399

Publisher

WILEY-LISS
DOI: 10.1002/ana.22163

Keywords

-

Ask authors/readers for more resources

The risk of developing progressive multifocal leukoencephalopathy increases with the duration of treatment with natalizumab. Planned dosage interruptions have been proposed as a means of decreasing cumulative risk. The clinical consequences of dosage interruption were evaluated in a single center cohort of natalizumab-treated patients. Medical records were reviewed for 84 patients identified with multiple sclerosis who received 12 or more infusions of natalizumab at an academic multiple sclerosis center. Eighty-one percent (68/84) underwent a dosage interruption, and 19% (16/84) had no interruption in natalizumab treatment. Of those with a treatment interruption, 27.9% (19/68) experienced a clinical relapse within 6 months of the suspension, whereas none of the patients with ongoing treatment experienced a flare during months 12 to 18 of treatment (p = 0.017, Fisher exact test). Survival analysis showed that Kaplan-Meier curves comparing dosage interruption to ongoing treatment diverged (p = 0.025). Median time from treatment interruption to relapse onset was 3 months. No clinical predictors associated with an increased risk of developing flares during dosage interruption were identified. Among the 19 patients who had a flare, 7 had severe flares, with a mean number of 16 Gad+ lesions on brain magnetic resonance imaging (range, 6-40). Their median Expanded Disability Status Scale at natalizumab interruption was 3.0 and increased to 6.0 during the flare (p = 0.0008). Natalizumab dosage interruption is associated with clinical flares and return of radiographic inflammatory disease activity. Some of these flares can be clinically severe, with a high number of contrast-enhanced lesions, suggesting a possible rebound of disease activity. ANN NEUROL 2010;68:395-399

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis

Xiaoyuan Zhou, Sneha Singh, Ryan Baumann, Patrick Barba, James Landefeld, Patrizia Casaccia, Ilana Katz Sand, Zongqi Xia, Howard Weiner, Tanuja Chitnis, Siddharthan Chandran, Peter Connick, David Otaegui, Tamara Castillo-Trivino, Stacy J. Caillier, Adam Santaniello, Gail Ackermann, Greg Humphrey, Laura Negrotto, Mauricio Farez, Reinhard Hohlfeld, Anne-Katrin Probstel, Xiaoming Jia, Jennifer Graves, Amit Bar-or, Jorge R. Oksenberg, Jeffery Gelfand, Michael R. Wilson, Elizabeth Crabtree, Scott S. Zamvil, Jorge Correale, Bruce A. C. Cree, Stephen L. Hauser, Rob Knight, Sergio E. Baranzini

Summary: This study found that the intra-individual variance observed by different collection strategies was dramatically lower than inter-individual variance, and shallow shotgun sequencing highly correlated with 16S sequencing. Participant house and recruitment site were the two largest sources of microbial variance, while higher microbial similarity was observed in household-matched participants.

MULTIPLE SCLEROSIS JOURNAL (2021)

Letter Clinical Neurology

Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?

Christian Cordano, Hao H. Yiu, Frederike C. Oertel, San Francisco, Jeffrey M. Gelfand, Stephen L. Hauser, Bruce A. C. Cree, Ari J. Green

ANNALS OF NEUROLOGY (2021)

Article Clinical Neurology

Identifying falls remotely in people with multiple sclerosis

Valerie J. Block, Erica A. Pitsch, Arpita Gopal, Chao Zhao, Mark J. Pletcher, Gregory M. Marcus, Jeffrey E. Olgin, Jill Hollenbach, Riley Bove, Bruce A. C. Cree, Jeffrey M. Gelfand

Summary: Falling is common in people with MS, but tends to be under-ascertained and under-treated. Those who fall tend to have greater disability, are more likely to have progressive MS, and take fewer steps on average. Multimodal fall screening may help identify those at greatest risk and improve patient care.

JOURNAL OF NEUROLOGY (2022)

Article Clinical Neurology

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Hans-Peter Hartung, Tobias Derfuss, Bruce A. C. Cree, Maria Pia Sormani, Krzysztof Selmaj, Jonathan Stutters, Ferran Prados, David MacManus, Hans-Martin Schneble, Estelle Lambert, Herve Porchet, Robert Glanzman, David Warne, Francois Curtin, Gabrielle Kornmann, Benedicte Buffet, David Kremer, Patrick Kury, David Leppert, Thomas Ruckle, Frederik Barkhof

Summary: The study did not meet its primary endpoint, but at 48 weeks participants treated with 18 mg/kg temelimab had fewer new T1-hypointense lesions. They also showed consistent, although statistically non-significant, reductions in brain atrophy and magnetization transfer ratio decrease compared to the placebo/comparator group. These trends were sustained over 96 weeks with no safety issues emerging.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series

Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M. Greenberg, Uma Kundu, Thomas Hach, Virginia DeLasHeras, Brian J. Ward, Joseph Berger

Summary: A descriptive analysis of COVID-19 infection in patients with multiple sclerosis receiving fingolimod or siponimod revealed that the risk of more severe COVID-19 in these patients seems to be similar to that reported in the general population and the MS population with COVID-19. However, limitations of spontaneous reporting, especially missing data, should be considered in the interpretation of these observations.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Article Clinical Neurology

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Bruce A. C. Cree, Douglas L. Arnold, Robert J. Fox, Ralf Gold, Patrick Vermersch, Ralph H. B. Benedict, Amit Bar-Or, Daniela Piani-Meier, Nicolas Rouyrre, Shannon Ritter, Ajay Kilaru, Goeril Karlsson, Gavin Giovannoni, Ludwig Kappos

Summary: This study evaluated the long-term efficacy and safety of siponimod in the treatment of SPMS. The results showed that continuous use of siponimod reduced the risk of disability progression and worsening in cognitive processing speed, and sustained efficacy was observed in relapse rate, brain atrophy, and inflammatory disease activity. No new safety signals were identified over the long term.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial

Douglas L. Arnold, Daniela Piani-Meier, Amit Bar-Or, Ralph H. B. Benedict, Bruce A. C. Cree, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Sophie Arnould, Frank Dahlke, Thomas Hach, Shannon Ritter, Goeril Karlsson, Ludwig Kappos, Robert J. Fox

Summary: The study found that siponimod treatment can slow down brain tissue damage and myelination process in patients with multiple sclerosis. This provides important information for better understanding of brain tissue integrity in patients with multiple sclerosis.

MULTIPLE SCLEROSIS JOURNAL (2022)

Review Clinical Neurology

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis

Stanley L. Cohan, Ralph H. B. Benedict, Bruce A. C. Cree, John DeLuca, Le H. Hua, Jerold Chun

Summary: Siponimod is an approved oral treatment for relapsing forms of multiple sclerosis, which targets the immune response and neural inflammation through regulating S1P(1) and S1P(5) receptors. It reduces lymphocyte migration to the central nervous system and exerts effects on various brain cells to decrease neurodegeneration and damage.

CNS DRUGS (2022)

Article Clinical Neurology

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce A. C. Cree, Krzysztof W. Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L. Arnold, Hans-Peter Hartung, Xavier Montalban, Eva K. Havrdova, James K. Sheffield, Neil Minton, Chun-Yen Cheng, Diego Silva, Ludwig Kappos, Jeffrey A. Cohen

Summary: This study characterizes the long-term safety and efficacy of ozanimod in the treatment of relapsing forms of multiple sclerosis. The findings confirm a favorable safety profile and sustained benefit in clinical outcomes and magnetic resonance imaging measures of disease activity.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants

Hari V. V. Kalluri, Matthew R. R. Rosebraugh, Thomas P. P. Misko, Adam Ziemann, Wei Liu, Bruce A. C. Cree

Summary: This study focuses on the safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab in healthy individuals and multiple sclerosis patients. The results demonstrate that elezanumab does not cause adverse events and has dose-dependent increases in cerebrospinal fluid concentrations.

ANNALS OF NEUROLOGY (2023)

Editorial Material Clinical Neurology

All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes

Bruce A. C. Cree

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Remote Observational Research for Multiple Sclerosis A Natural Experiment

Riley Bove, Shane Poole, Richard Cuneo, Sasha Gupta, Joseph Sabatino, Meagan Harms, Tifffany Cooper, William Rowles, Nicolette Miller, Refujia Gomez, Robin Lincoln, Kira McPolin, Kyra Powers, Adam Santaniello, Adam Renschen, Carolyn J. Bevan, Jeffrey M. Gelfand, Douglas S. Goodin, Chu-Yueh Guo, Andrew R. Romeo, Stephen L. Hauser, Bruce Anthony Campbell Cree, UCSF MS-EPIC Team

Summary: This study found that remote evaluations can reduce the costs of research participation for patients, while providing a reasonable evaluation of disability trajectory longitudinally. This could inform the design of remote research that is more inclusive of diverse participants.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Review Clinical Neurology

Secondary Progressive Multiple Sclerosis A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies

Tjalf Ziemssen, Virender Bhan, Jeremy Chataway, Tanuja Chitnis, Bruce Anthony Campbell Cree, Eva Kubala Havrdova, Ludwig Kappos, Pierre Labauge, Aaron Miller, Jin Nakahara, Celia Oreja-Guevara, Jacqueline Palace, Barry Singer, Maria Trojano, Ashwini Patil, Benedict Rauser, Thomas Hach

Summary: There are many challenges in accurately diagnosing and managing SPMS due to the lack of definitive criteria for the transition from RRMS to SPMS. This review discusses the diagnostic criteria/definition and the heterogeneity of SPMS patient populations, and emphasizes the importance of early identification through prospective/retrospective tools to improve outcomes with approved treatments. Effective interventions require ongoing patient-clinician dialogue within a multidisciplinary team.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Clinical Neurology

SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis

Bruce A. C. Cree, Rachel Maddux, Amit Bar-Or, Hans-Peter Hartung, Amandeep Kaur, Elizabeth Brown, Yicong Li, Yanhua Hu, James K. Sheffield, Diego Silva, Sarah Harris

Summary: This study investigated the serologic response, predictors of response, and clinical outcomes associated with SARS-CoV-2 vaccination and infection in RMS patients treated with ozanimod. The results showed that most ozanimod-treated RMS patients mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of individual characteristics or lymphocyte count levels. Additionally, mRNA vaccination predicted higher levels of serum antibodies.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

No Data Available